

IN THE CLAIMS:

Claims 1-14. (Cancelled).

Claim 15. (New) A method of treating an autoimmune condition comprising administering an IL-174 agonist to a mammal.

Claim 16. (New) The method of Claim 15, wherein the autoimmune condition comprises:

- a) multiple sclerosis;
- b) systemic lupus erythematosus;
- c) rheumatoid arthritis;
- d) diabetes; or
- e) psoriasis.

Claim 17. (New) The method of Claim 15, wherein the agonist comprises a polypeptide of SEQ ID NO:2.

Claim 18. (New) The method of Claim 15, wherein the treating or administering comprises use of an adenoviral construct.

Claim 19. (New) A method of administering or treatment with an agonist of IL-174 (SEQ ID NO:2) to a mammal exhibiting a TH1-mediated condition.

Claim 20. (New) The method of Claim 19, wherein the condition comprises an inflammatory condition.

Claim 21. (New) The method of Claim 19, wherein the condition comprises:

- a) Crohn's disease;
- b) ulcerative colitis;
- c) pancreatitis;
- d) hepatitis; or
- e) eosinophilic gastritis.

Claim 22. (New) A method of:

- a) stimulating an innate immune response;
- b) augmenting an inflammatory response from epithelial or fibroblast cells;
- c) promoting extra medulary hematopoiesis;
- d) augmenting antibody response in serum and fecal matter;
- e) treating an infectious disease; or
- f) treating a wound healing response;

comprising administering an IL-174 agonist to the mammal.

Claim 23. (New) A method of:

- a) preventing mammalian granuloma formation;
- b) treating a TH2-mediated condition;
- c) directing a mammalian immune response away from a TH2-type response;
- d) blocking eosinophil attraction, tissue remodeling, or fibrosis; or

comprising administering an IL-174 antagonist to the mammal.

Claim 24. (New) The method of Claim 23, wherein:

- a) the eosinophils are attracted to the liver or intestine;
- b) the fibrosis is pancreatic duct or peribiliary fibrosis;
- c) the antagonist suppresses production of IL-4, IL-5, and/or IL-13; or
- d) the TH2-mediated condition is dermatitis.

Claim 25. (New) The method of Claim 23, wherein the antagonist comprises a binding composition which specifically binds to a polypeptide of SEQ ID NO:2.

Claim 26. (New) The method of Claim 25, wherein the composition comprises:

- a) a polyclonal antibody;
- b) a monoclonal antibody; or
- c) an antibody fragment.

Claim 27. (New) A method of treating a mammal exhibiting an allergic condition comprising administering an effective amount of an IL-174 antagonist sufficient to ameliorate the allergic condition, wherein the antagonist is an anti-sense nucleic acid.